(2-(4-bromophenyl)-4,5-dihydrooxazol-4-yl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-(4-bromophenyl)-4,5-dihydrooxazol-4-yl)methanol
• 英文别名: [2-(4-Bromophenyl)-4,5-dihydro-1,3-oxazol-4-yl]methanol
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.099
• InChiKey: KPXKRWXNJWQQQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-溴苯腈 、 丝氨醇 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 10.0h， 以80%的产率得到(2-(4-bromophenyl)-4,5-dihydrooxazol-4-yl)methanol
  参考文献：
  名称：

  （±）-杨凌霉素及其类似物的高效合成和抗菌评价。

  摘要：

  为大规模制备（±）-杨霉素及其类似物开发了一种有效的合成途径。合成了（±）-杨凌霉素的三个系列衍生物，并通过NMR和ESI-MS光谱数据的分析阐明了所有化合物的结构。此外，通过微肉汤稀释法系统地评估了它们对七种细菌的抗菌活性，其中大多数显示出相当大的活​​性。值得注意的是，化合物5b，5c，5d，6g和7被认为是最有前途的候选候选物，枯草芽孢杆菌的MIC峰值为0.98μg·mL（-1），优于阳性对照（ MIC = 3.91μg·mL（-1））。以上结果可能为基于（±）-杨凌霉素的新型抗菌药物的设计和合成奠定坚实的基础。

  DOI：

  10.3390/molecules21010096

文献信息

• Novel oxazolidinone derivatives
  申请人：Rhee Keol Jae

  公开号：US20070155798A1

  公开（公告）日：2007-07-05

  The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium . Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic. Data supplied from the esp@cenet database—Worldwide

  本发明涉及一种新型的噁唑烷酮衍生物及其制备方法和含有该衍生物的药物组合物，用于抗生素。本发明的噁唑烷酮衍生物对广谱细菌具有抑制活性，且毒性较低。通过将具有羟基的化合物与氨基酸或磷酸反应制备的前药，在溶解性方面具有优异的效率。此外，本发明的衍生物可能对各种人类和动物病原体具有强效的抗菌活性，包括革兰氏阳性菌，如葡萄球菌、肠球菌和链球菌，厌氧微生物，如拟杆菌和梭状芽孢杆菌，以及耐酸微生物，如结核分枝杆菌和鸟型分枝杆菌。因此，含有噁唑烷酮的组合物用于抗生素。数据来源于esp@cenet数据库-全球。
• NOVEL OXAZOLIDINONE DERIVATIVES
  申请人：Rhee Jae Keol

  公开号：US20090192197A1

  公开（公告）日：2009-07-30

  The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia , and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium . Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.

  本发明涉及一种新型的噁唑烷酮衍生物及其制备方法和制备的药物组合物，用于抗生素。本发明的噁唑烷酮衍生物对广谱细菌具有抑制活性，毒性较低。通过将具有羟基的化合物与氨基酸或磷酸反应制备的前药，在水中具有出色的溶解效率。此外，本发明的衍生物可能对各种人类和动物病原体产生强效的抗菌活性，包括革兰氏阳性细菌，如葡萄球菌、肠球菌和链球菌，厌氧微生物，如拟杆菌和梭菌，以及耐酸微生物，如结核分枝杆菌和埃迪克曼分枝杆菌。因此，包含噁唑烷酮衍生物的组合物可用于抗生素。
• Oxazolidinone derivatives
  申请人：Dong-A Pharmaceutical Co., Ltd.

  公开号：EP2305657A2

  公开（公告）日：2011-04-06

  The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.

  本发明涉及噁唑烷酮的新型衍生物、其方法以及包含该衍生物的用于抗生素的药物组合物。本发明的噁唑烷酮衍生物对广谱细菌具有抑制活性，毒性较低。通过使具有羟基的化合物与氨基酸或磷酸盐反应制备的原药在水中的溶解度效率极高。此外，本发明的衍生物可对各种人类和动物病原体发挥强效抗菌活性，包括革兰氏阳性细菌（如葡萄球菌、肠球菌和链球菌）、厌氧微生物（如乳酸杆菌和梭状芽孢杆菌）以及耐酸微生物（如结核分枝杆菌和鸟疫分枝杆菌）。因此，包含噁唑烷酮的组合物可用于抗生素。
• EP1699784B1
  申请人：——

  公开号：EP1699784B1

  公开（公告）日：2011-06-29
• US7816379B2
  申请人：——

  公开号：US7816379B2

  公开（公告）日：2010-10-19